A randomised, double-blind, placebo-controlled, parallel group, 52 weeks phase IV trial to evaluate efficacy and safety of oral, once daily empagliflozin in elderly Japanese patients with type 2 diabetes mellitus and insufficient glycaemic control

In elderly Japanese patients with T2DM and insufficient glycaemic control, treatment with empagliflozin (10 mg) as an add-on therapy to OADs and in treatment naive patients demonstrated a statistically significant and clinically meaningful improvement in the change from baseline in HbA1c after 52 weeks of treatment compared with placebo. Empagliflozin as an add-on therapy to OADs and in treatment naive patients was well tolerated and no new safety findings were observed.